{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:48:14Z","timestamp":1789012094967,"version":"build-2803163510"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clim.2022.108982","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T14:06:59Z","timestamp":1647526019000},"page":"108982","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["What we have learned about lymphocytic variant hypereosinophilic syndrome: A systematic literature review"],"prefix":"10.1016","volume":"237","author":[{"given":"Yiyun","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2022.108982_bb0005","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WOX.0b013e31827f4192","article-title":"ICON: eosinophil disorders","volume":"5","author":"Valent","year":"2012","journal-title":"World Allergy Organ J."},{"key":"10.1016\/j.clim.2022.108982_bb0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.iac.2007.07.002","article-title":"Lymphocytic variant hypereosinophilic syndromes","volume":"27","author":"Roufosse","year":"2007","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.clim.2022.108982_bb0020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3324\/haematol.2013.091264","article-title":"Episodic angioedema with eosinophilia (Gleich syndrome) is a multilineage cell cycling disorder","volume":"100","author":"Khoury","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2022.108982_bb0025","article-title":"Abnormal T-cell phenotype in episodic angioedema with hypereosinophilia (Gleich\u2019s syndrome): frequency, clinical implication and prognosis","author":"Abisror","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2022.108982_bb0030","first-page":"1086","article-title":"CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder","volume":"100","author":"Lef\u00e8vre","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2022.108982_bb0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clim.2022.108982_bb0040","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17615","article-title":"Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis","author":"Williams","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2022.108982_bb0045","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0050","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MD.0000000000000088","article-title":"The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype","volume":"93","author":"Lef\u00e8vre","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clim.2022.108982_bb0060","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3389\/fimmu.2020.01765","article-title":"Eosinophilia associated with CD3-CD4+ T cells: characterization and outcome of a single-center cohort of 26 patients","volume":"11","author":"Carpentier","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJM199402243300804","article-title":"Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome","volume":"330","author":"Cogan","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1309\/AJCP1NA3YCHCDEIG","article-title":"Blood flow cytometry in S\u00e9zary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up","volume":"143","author":"Novelli","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.clim.2022.108982_bb0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2249.1994.tb06624.x","article-title":"Progressive increase of CD7- T cells in human blood lymphocytes with ageing","volume":"98","author":"Kukel","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0080","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0002-9343(87)90458-X","article-title":"Peripheral T cell lymphoma presenting as hypereosinophilia with vasculitis. Clinical, pathologic, and immunologic features","volume":"82","author":"O\u2019Shea","year":"1987","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0085","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1172\/JCI118417","article-title":"Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells","volume":"97","author":"Schanden\u00e9","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2022.108982_bb0090","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00042737-199602000-00017","article-title":"Long-term outcome of idiopathic hypereosinophilic syndrome\u2013transition to eosinophilic gastroenteritis and clonal expansion of T-cells","volume":"8","author":"Bauer","year":"1996","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2022.108982_bb0095","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1365-2141.1996.d01-1482.x","article-title":"Eosinophilia associated with proliferation of CD(3+)4-(8-) alpha beta+ T cells with chromosome 16 anomalies","volume":"92","author":"Kitano","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2022.108982_bb0100","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.V87.4.1416.bloodjournal8741416","article-title":"A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5","volume":"87","author":"Brugnoni","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0105","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1084\/jem.183.3.1071","article-title":"Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia","volume":"183","author":"Simon","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0110","first-page":"918","article-title":"Wells\u2019 syndrome: a pathogenic role for circulating CD4+CD7- T cells expressing interleukin-5 mRNA","volume":"136","author":"Yagi","year":"1997","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.clim.2022.108982_bb0115","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0091-6749(98)70279-9","article-title":"Role of gamma\/delta T cells in a patient with CD4+CD3- lymphocytosis, hypereosinophilia, and high levels of IgE","volume":"102","author":"Bank","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0120","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/blood.V94.3.994.415k26_994_1002","article-title":"T-cell receptor-independent activation of clonal Th2 cells associated with chronic hypereosinophilia","volume":"94","author":"Roufosse","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0125","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199910073411503","article-title":"Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia","volume":"341","author":"Simon","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0002-9343(99)00263-6","article-title":"Indolent course of a patient with hypereosinophilic syndrome associated with clonal T-cell proliferation","volume":"107","author":"Zenone","year":"1999","journal-title":"Am. J. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0135","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1365-2141.2000.02097.x","article-title":"Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome","volume":"109","author":"Roufosse","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2022.108982_bb0140","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood.V96.13.4285","article-title":"Interferon alpha prevents spontaneous apoptosis of clonal Th2 cells associated with chronic hypereosinophilia","volume":"96","author":"Schanden\u00e9","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0145","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1159\/000053723","article-title":"Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia","volume":"124","author":"Simon","year":"2001","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0150","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1521-4141(200104)31:4<1037::AID-IMMU1037>3.0.CO;2-#","article-title":"Clonal Th2 cells associated with chronic hypereosinophilia: TARC-induced CCR4 down-regulation in vivo","volume":"31","author":"de Lavareille","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10428190109097684","article-title":"The hypereosinophilic syndrome associated with CD4+CD3- helper type 2 (Th2) lymphocytes","volume":"42","author":"Bank","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.clim.2022.108982_bb0160","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF02982042","article-title":"More than 13 years of hypereosinophila associated with clonal CD3-CD4+ lymphocytosis of TH2\/TH0 type","volume":"75","author":"Sugimoto","year":"2002","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.clim.2022.108982_bb0165","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1067\/mai.2002.127003","article-title":"High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome","volume":"110","author":"de Lavareille","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0170","first-page":"ECR24","article-title":"Hypereosinophilia with abnormal T cells, trisomy 7 and elevated TARC serum level","volume":"88","author":"Roumier","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2022.108982_bb0175","first-page":"1623","article-title":"Clonal T-helper lymphocytes and elevated IL-5 levels in episodic angioedema and eosinophilia (Gleich\u2019s syndrome)","volume":"44","author":"Morgan","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.clim.2022.108982_bb0180","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0185","first-page":"238","article-title":"Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes","volume":"89","author":"Bassan","year":"2004","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2022.108982_bb0190","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report","volume":"127","author":"Pitini","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2022.108982_bb0195","first-page":"753","article-title":"6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome","volume":"90","author":"Ravoet","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2022.108982_bb0200","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.exphem.2005.06.027","article-title":"Defective CD3gamma gene transcription is associated with NFATc2 overexpression in the lymphocytic variant of hypereosinophilic syndrome","volume":"33","author":"Willard-Gallo","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.clim.2022.108982_bb0205","first-page":"ECR42","article-title":"The achievement of complete molecular remission after autologous stem cell transplantation for T-cell lymphoma with associated hypereosinophilia, rare aberration t(6;11) and elevated IL-4 and IgE","volume":"91","author":"Helbig","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2022.108982_bb0210","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.leukres.2006.10.005","article-title":"\u2018Idiopathic\u2019 eosinophilia with an occult T-cell clone: prevalence and clinical course","volume":"31","author":"Vaklavas","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clim.2022.108982_bb0215","first-page":"401","article-title":"Cyclical hypereosinophilia with skin manifestations and a clonal T cell population","volume":"18","author":"Gonz\u00e1lez Delgado","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.clim.2022.108982_bb0220","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1468-3083.2007.02464.x","article-title":"T-cell-associated hypereosinophilic syndrome: case report and an appraisal of the new classification","volume":"22","author":"Zaccaria","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2022.108982_bb0225","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00277-008-0505-9","article-title":"Resolution of left and right ventricular thrombosis secondary to hypereosinophilic syndrome (lymphoproliferative variant) with reduced intensity conditioning allogenic stem cell transplantation","volume":"87","author":"Bergua","year":"2008","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.clim.2022.108982_bb0230","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3324\/haematol.2008.005447","article-title":"T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome","volume":"94","author":"Helbig","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2022.108982_bb0235","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2008-08-175091","article-title":"Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways","volume":"114","author":"Ravoet","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0240","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/j.ijcard.2008.11.018","article-title":"Atypical cardiac manifestation of hypereosinophilic syndrome and reversible cardiotoxicity to imatinib","volume":"139","author":"Garcia-Alvarez","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.clim.2022.108982_bb0245","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2230.2010.03790.x","article-title":"Lymphocytic variant of hypereosinophilic syndrome","volume":"35","author":"Zaheri","year":"2010","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.clim.2022.108982_bb0250","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-3083.2010.02436.x","article-title":"The proportion of CD3- CD4+ T-cell population remained unaffected after corticosteroids treatment for lymphocytic variant hypereosinophilic syndrome (L-HES)","volume":"72","author":"Helbig","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0255","first-page":"79","article-title":"Effectiveness of a combination of cyclosporine a, suplatast tosilate and prednisolone on periodic oscillating hypereosinophilia","volume":"4","author":"Imashuku","year":"2011","journal-title":"Int. Med. Case Rep. J."},{"key":"10.1016\/j.clim.2022.108982_bb0260","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1007\/s00415-011-6089-7","article-title":"Dissection of the posterior inferior cerebellar artery in the hypereosinophilic syndrome","volume":"258","author":"van Gaalen","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.clim.2022.108982_bb0265","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/blood-2012-12-472720","article-title":"Chronic active Epstein-Barr virus infection: a novel cause of lymphocytic variant hypereosinophilic syndrome","volume":"121","author":"Klion","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0270","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1183\/09031936.00099812","article-title":"Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome","volume":"41","author":"Cordier","year":"2013","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.clim.2022.108982_bb0275","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.intimp.2013.04.033","article-title":"Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome","volume":"16","author":"Tabata","year":"2013","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.clim.2022.108982_bb0280","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/j.oooo.2013.03.017","article-title":"Hypereosinophilic syndrome - lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations","volume":"116","author":"d\u2019Elb\u00e9e","year":"2013","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.clim.2022.108982_bb0285","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3315\/jdcr.2014.1185","article-title":"Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma","volume":"8","author":"Mahajan","year":"2014","journal-title":"J. Dermatol. Case Rep."},{"key":"10.1016\/j.clim.2022.108982_bb0290","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cup.12454","article-title":"CD30+ clonal T-cell lymphoid proliferation of the skin in a patient with hypereosinophilic syndrome","volume":"42","author":"Kempf","year":"2015","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.clim.2022.108982_bb0295","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3109\/10428194.2014.976823","article-title":"Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma","volume":"56","author":"Roufosse","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.clim.2022.108982_bb0300","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood-2015-10-674945","article-title":"Lymphocytic variant of hypereosinophilic syndrome mimicking peripheral T-cell lymphoma in a young woman","volume":"127","author":"King","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0305","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0310","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.ejim.2016.05.024","article-title":"Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance- extended follow-up","volume":"35","author":"Helbig","year":"2016","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0315","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5045\/br.2017.52.1.71","article-title":"A case of lymphocytic variant hypereosinophilic syndrome with sub-diagnostic systemic mastocytosis","volume":"52","author":"Jain","year":"2017","journal-title":"Blood Res."},{"key":"10.1016\/j.clim.2022.108982_bb0320","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/ejh.12842","article-title":"IgG4-related disease and lymphocyte-variant hypereosinophilic syndrome: a comparative case series","volume":"98","author":"Carruthers","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.clim.2022.108982_bb0325","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of Hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors Tofacitinib and Ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.clim.2022.108982_bb0330","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.amjms.2017.03.030","article-title":"Lymphocyte-variant Hypereosinophilic syndrome with eosinophilic myocarditis treated with steroids and Pegylated interferon alfa-2a","volume":"355","author":"Cheung","year":"2018","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.clim.2022.108982_bb0335","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pai.12809","article-title":"Mepolizumab-a novel option for the treatment of hypereosinophilic syndrome in childhood","volume":"29","author":"Schwarz","year":"2018","journal-title":"Pediatr. Allergy Immunol."},{"key":"10.1016\/j.clim.2022.108982_bb0340","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0345","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1016\/j.ejim.2018.08.004","article-title":"Lymphocytic variant hypereosinophilia: a challenging diagnosis of a rare disease with pleomorphic clinical picture","volume":"57","author":"Orofino","year":"2018","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0350","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-negative Hypereosinophilic syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2022.108982_bb0355","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jdcr.2019.05.026","article-title":"Lymphocyte-variant hypereosinophilic syndrome presenting as chronic dermatitis and responding to mycophenolic acid","volume":"5","author":"Dou","year":"2019","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.clim.2022.108982_bb0360","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/ddg.13926_g","article-title":"Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab","volume":"17","author":"Buttgereit","year":"2019","journal-title":"J. Dtsch Dermatol. Ges"},{"key":"10.1016\/j.clim.2022.108982_bb0365","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.jaip.2019.04.039","article-title":"Romidepsin is an effective and well-tolerated therapy in CD3-CD4+ lymphocyte-variant hypereosinophilic syndrome: a case report","volume":"7","author":"Baulier","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clim.2022.108982_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2019.151412","article-title":"Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with Hypereosinophilia: a reference laboratory experience","volume":"44","author":"Shi","year":"2020","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.clim.2022.108982_bb0375","doi-asserted-by":"crossref","first-page":"e128","DOI":"10.1016\/j.clml.2019.11.006","article-title":"Dramatic and durable responses to Romidepsin in two patients with the lymphocytic variant of Hypereosinophilic syndrome","volume":"20","author":"Abbasi","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clim.2022.108982_bb0380","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1111\/bjh.16332","article-title":"Pegylated interferon alpha 2a is an effective and well-tolerated treatment option for lymphocyte-variant hypereosinophilic syndrome","volume":"188","author":"Choi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.clim.2022.108982_bb0385","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaip.2019.08.049","article-title":"Assessment of T-cell polarization on the basis of surface marker expression: diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome","volume":"8","author":"Ledoult","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clim.2022.108982_bb0390","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/ddg.14083","article-title":"Recurrent hemorrhagic blisters: an atypical presentation of lymphocytic hypereosinophilic syndrome with cutaneous manifestations","volume":"18","author":"Rodr\u00edguez-Lomba","year":"2020","journal-title":"J. Dtsch Dermatol. Ges"},{"key":"10.1016\/j.clim.2022.108982_bb0395","doi-asserted-by":"crossref","first-page":"376","DOI":"10.23736\/S0392-0488.18.06046-7","article-title":"Lymphocytic variant of hypereosinophilic syndrome presenting with polymorphic cutaneous manifestations and nonspecific histopathological findings","volume":"155","author":"Cusini","year":"2020","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"10.1016\/j.clim.2022.108982_bb0400","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/jclinpath-2019-206255","article-title":"Causes of double-negative T-cell lymphocytosis in children and adults","volume":"73","author":"Liapis","year":"2020","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.clim.2022.108982_bb0405","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2020008436","article-title":"An unusual cause for neoplastic eosinophilia: nothing on morphology","volume":"136","author":"Goel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0410","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.2020009234","article-title":"A case of lymphocytic variant hypereosinophilic syndrome in an elderly patient","volume":"137","author":"Moshref","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clim.2022.108982_bb0415","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PAS.0000000000001604","article-title":"Two cases with features of lymphocyte variant Hypereosinophilic syndrome with STAT3 SH2 domain mutations","volume":"45","author":"Fernandez-Pol","year":"2021","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.clim.2022.108982_bb0420","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ajcp\/aqaa227","article-title":"Reactive eosinophil proliferations in tissue and the lymphocytic variant of Hypereosinophilic syndrome","volume":"155","author":"King","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.clim.2022.108982_bb0425","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/cyto.b.21874","article-title":"Lymphocytic variant of hypereosinophilic syndrome: a report of seven cases from a single institution","volume":"100","author":"Hu","year":"2021","journal-title":"Cytometry B Clin. Cytom."},{"key":"10.1016\/j.clim.2022.108982_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2021-242695","article-title":"Bullous pemphigoid-like rash revealing hypereosinophilic syndrome","volume":"14","author":"Khallaayoune","year":"2021","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.clim.2022.108982_bb0435","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25945","article-title":"Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: data from 151 patients","volume":"95","author":"Rohmer","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clim.2022.108982_bb0440","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.iac.2007.07.001","article-title":"Cardiovascular manifestations of hypereosinophilic syndromes","volume":"27","author":"Ogbogu","year":"2007","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.clim.2022.108982_bb0445","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The Spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clim.2022.108982_bb0450","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3324\/haematol.2009.010421","article-title":"Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations","volume":"94","author":"Roufosse","year":"2009","journal-title":"Haematologica"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622000638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661622000638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:05:16Z","timestamp":1761494716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661622000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":90,"alternative-id":["S1521661622000638"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2022.108982","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What we have learned about lymphocytic variant hypereosinophilic syndrome: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2022.108982","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108982"}}